Gilder Gagnon Howe & Co. LLC Decreases Position in Glaukos Corporation $GKOS

by · The Cerbat Gem

Gilder Gagnon Howe & Co. LLC decreased its stake in Glaukos Corporation (NYSE:GKOS – Free Report) by 16.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 700,634 shares of the medical instruments supplier’s stock after selling 135,895 shares during the period. Gilder Gagnon Howe & Co. LLC owned 1.22% of Glaukos worth $72,369,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Park Place Capital Corp lifted its position in Glaukos by 68.4% in the second quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock valued at $41,000 after acquiring an additional 162 shares during the last quarter. AlphaQuest LLC increased its position in shares of Glaukos by 5,754.5% during the second quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock worth $67,000 after purchasing an additional 633 shares in the last quarter. Parkside Financial Bank & Trust lifted its holdings in shares of Glaukos by 909.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,252 shares of the medical instruments supplier’s stock valued at $129,000 after purchasing an additional 1,128 shares during the last quarter. Bayforest Capital Ltd acquired a new stake in shares of Glaukos in the 1st quarter valued at about $141,000. Finally, M&T Bank Corp purchased a new position in Glaukos during the 2nd quarter worth approximately $203,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 315 shares of Glaukos stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $105.00, for a total value of $33,075.00. Following the sale, the chief financial officer owned 50,488 shares of the company’s stock, valued at approximately $5,301,240. The trade was a 0.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gilbert H. Kliman sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $107.27, for a total value of $536,350.00. Following the transaction, the director owned 34,905 shares in the company, valued at $3,744,259.35. The trade was a 12.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 24,655 shares of company stock worth $2,310,025 over the last 90 days. Company insiders own 5.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. UBS Group reiterated a “buy” rating and issued a $140.00 price objective on shares of Glaukos in a research note on Monday, November 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a research report on Wednesday, October 8th. The Goldman Sachs Group began coverage on shares of Glaukos in a research note on Wednesday, October 1st. They set a “buy” rating and a $103.00 price target for the company. Needham & Company LLC lifted their price objective on shares of Glaukos from $117.00 to $125.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Wells Fargo & Company upped their target price on shares of Glaukos from $120.00 to $122.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $120.62.

Check Out Our Latest Research Report on Glaukos

Glaukos Stock Performance

NYSE:GKOS opened at $109.00 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47. The firm has a market cap of $6.26 billion, a price-to-earnings ratio of -70.78 and a beta of 0.69. The firm’s fifty day moving average price is $91.77 and its 200 day moving average price is $92.79. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $163.71.

Glaukos (NYSE:GKOS – Get Free Report) last released its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.11. The company had revenue of $133.54 million during the quarter, compared to analysts’ expectations of $122.55 million. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. The business’s revenue was up 38.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.28) EPS. On average, sell-side analysts expect that Glaukos Corporation will post -1.08 EPS for the current year.

Glaukos Profile

(Free Report)

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

Featured Stories

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS – Free Report).